145 related articles for article (PubMed ID: 21678117)
1. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.
Mirzoeva OK; Hann B; Hom YK; Debnath J; Aftab D; Shokat K; Korn WM
J Mol Med (Berl); 2011 Sep; 89(9):877-89. PubMed ID: 21678117
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
3. The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.
Faia K; White K; Murphy E; Proctor J; Pink M; Kosmider N; McGovern K; Kutok J
PLoS One; 2018; 13(8):e0200725. PubMed ID: 30067771
[TBL] [Abstract][Full Text] [Related]
4. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
[TBL] [Abstract][Full Text] [Related]
6. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
Sun Q; Chu Y; Zhang N; Chen R; Wang L; Wu J; Dong Y; Li H; Wang L; Tang L; Zhan C; Zhang JQ
J Med Chem; 2024 May; 67(9):7330-7358. PubMed ID: 38661655
[TBL] [Abstract][Full Text] [Related]
8. Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression.
Parkman GL; Turapov T; Kircher DA; Burnett WJ; Stehn CM; O'Toole K; Culver KM; Chadwick AT; Elmer RC; Flaherty R; Stanley KA; Foth M; Lum DH; Judson-Torres RL; Friend JE; VanBrocklin MW; McMahon M; Holmen SL
Mol Cancer Ther; 2024 Mar; 23(3):301-315. PubMed ID: 37931033
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
10. A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.
Rebecca VW; Nicastri MC; McLaughlin N; Fennelly C; McAfee Q; Ronghe A; Nofal M; Lim CY; Witze E; Chude CI; Zhang G; Alicea GM; Piao S; Murugan S; Ojha R; Levi SM; Wei Z; Barber-Rotenberg JS; Murphy ME; Mills GB; Lu Y; Rabinowitz J; Marmorstein R; Liu Q; Liu S; Xu X; Herlyn M; Zoncu R; Brady DC; Speicher DW; Winkler JD; Amaravadi RK
Cancer Discov; 2017 Nov; 7(11):1266-1283. PubMed ID: 28899863
[TBL] [Abstract][Full Text] [Related]
11. MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Jokinen E; Koivunen JP
Ther Adv Med Oncol; 2015 May; 7(3):170-80. PubMed ID: 26673580
[TBL] [Abstract][Full Text] [Related]
12. Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Filippi-Chiela EC; Bueno e Silva MM; Thomé MP; Lenz G
Autophagy; 2015; 11(7):1099-113. PubMed ID: 25701485
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
[TBL] [Abstract][Full Text] [Related]
14. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma.
Mirzoeva OK; Collisson EA; Schaefer PM; Hann B; Hom YK; Ko AH; Korn WM
Mol Cancer Ther; 2013 Oct; 12(10):2213-25. PubMed ID: 23918833
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
16. The role of amino acid metabolism alterations in pancreatic cancer: From mechanism to application.
Fu S; Xu S; Zhang S
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188893. PubMed ID: 37015314
[TBL] [Abstract][Full Text] [Related]
17. Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in vitro.
Qian X; Bi QY; Wang ZN; Han F; Liu LM; Song LB; Li CY; Zhang AQ; Ji XM
J Ethnopharmacol; 2023 May; 307():116198. PubMed ID: 36690307
[TBL] [Abstract][Full Text] [Related]
18. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer.
Yang PW; Xu PL; Cheng CS; Jiao JY; Wu Y; Dong S; Xie J; Zhu XY
J Ethnopharmacol; 2022 Oct; 297():115516. PubMed ID: 35817247
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
20. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
